Note: Descriptions are shown in the official language in which they were submitted.
CA 02698500 2010-11-26
CREATINE SUGAR AMIDES AND SALTS TIIEREOF
Related Applications
[0001] The present application is related to United States patent applications
pubished as
2009-0297685 and 2009-0298877.
Field Of The Invention
[0002] The present invention relates to structures, methods for producing
creatine imino
sugar amides and salts thereof. Specifically, the present invention relates to
compounds
comprising an imino sugar bound to creatine, via an amide linkage, and formed
salts thereof
that are particularly well suited for oral and parenteral use.
Background of the Invention
[0003] Creatine is a naturally occurring amino acid that is derived from the
amino acids;
glycine, arginine and methionine. Although it is ingested from meats and fish,
the human
body also synthesizes its own creatine. About 65% of creatine is stored in the
musculature of
mammals in the form of phosphocreatine (creatine bound to a phosphate
molecule), and
utilized mostly as a source of energy for muscle. Oral supplementation of
creatine has been
shown to increase creatine concentration in muscle, and also enables an
increase in the
resynthesis of phosphocreatine, resulting in a rapid replenishment of ATP
within the first two
minutes of the start of exercise.
[0004] The beneficial effects of creatine supplementation with regard to
skeletal muscle
are apparently not restricted to the role of creatine in energy metabolism.
Creatine
supplementation in combination with strength training results in specific,
measurable
physiological changes in skeletal muscle compared to strength training alone.
For example,
creatine supplementation amplifies the strength training-induced increase of
human skeletal
satellite cells as well as the number of myonuclei in human skeletal muscle
fibers. Satellite
cells, stem cells of adult muscle, are normally in a quiescent state and
become activated to
1
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
fulfill roles of routine maintenance, repair and hypertrophy. Postnatal muscle
growth
involves both myofiber hypertrophy and increased numbers of myonuclei - the
source of
which are satellite cells.
[0005] Imino sugars constitute a major class of naturally occurring molecules
that have
important and diverse biological functions. Imino sugars may be pentose,
hexose or heptose
sugars where at least one oxygen-containing group is replaced by a nitrogen-
containing
group. These imino sugars are useful in pharmacology, since they have been
found to play
major roles in the selective inhibition of various enzymatic functions.
[0006] Many have attempted to address issues such as stability, solubility,
and
bioavailability of creatine and imino sugars, independently, through the use
of salts, esters,
and amides. However, compounds of an imino sugar and a creatine bound via an
amide bond
are not known. It is commonly understood that hydrolysis of amides is more
difficult to
accomplish than the hydrolysis of esters. Therefore, an amide of creatine and
an imino sugar
would be more stable in solution than the related ester.
Summary of the Invention
[0007] In the present invention, compounds and methods of production are
disclosed,
wherein the compounds comprise an imino sugar bound to creatine, via an amide
linkage, and
having a structure corresponding to Formula 1:
Formula 1
0 R1
H2N Y N "'A N OH
NH
R2 n OH
OH
where R1 = H, OH, or CHZOH;
R2 = H, OH, CH3 or CH2OH; and
n = 0, 1 or 2.
[0008] An additional aspect of the present invention discloses a method for
producing the
compound corresponding to Formula 1.
[0009] In a further aspect of the present invention, the compound
corresponding to Formula
I may be combined with one or more pharmaceutically acceptable carriers to
form a
nutritional composition, which can be orally administered to a subject.
2
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
[0010] In an additional aspect of the present invention, creatine imino sugar
amide salts,
methods for their production, and solid compositions comprising said creatine
imino sugar
amide salts, are disclosed. Specifically, the creatine imino sugar amide salts
comprise an
acceptable inorganic or organic acid and a creatine imino sugar amide.
[0011] An additional aspect of the present invention discloses a method for
producing
creatine imino sugar amide salts.
[0012] In a further aspect of the present invention, the creatine imino sugar
amide salts may
be combined with one or more pharmaceutically acceptable carriers to form a
nutritional
composition, which can be administered to a subject.
Detailed Description of the Invention
[0013] In the following description, for the purposes of explanation, numerous
specific
details are set forth in order to provide a thorough understanding of the
present invention. It
will be apparent, however, to one skilled in the art that the present
invention may be practiced
without these specific details.
[0014] The present invention relates to compounds of creatine imino sugar
amides, salts
thereof, and their routes of syntheses. Specific benefits are conferred by the
creatine portion
of the compound in addition to, and separate from, the imino sugar
substituent. Additionally,
the present invention provides for combinations of creatine imino sugar amides
and inorganic
or organic acid, which are free of physiologically unsafe additives.
Furthermore, the present
invention is particularly well suited for use in tablets, capsules, powders,
granules, powdered
beverage mixes and other forms known in the art of dietary supplements.
[0015] As used herein, `creatine' refers to the chemical N-methyl-N-guanyl
Glycine, (CAS
Registry No. 57-00-1), also known as, (alpha-methyl guanido) acetic acid, N-
(aminoiminomethyl)-N-glycine, Methylglycocyamine, Methylguanidoacetic Acid, or
N-
Methyl-N-guanylglycine. Additionally, as used herein, `creatine' also includes
derivatives of
creatine such as esters and salts, as well as other derivatives, including
derivatives having
pharmacoproperties upon metabolism to an active form.
[0016] As used herein, `deoxynojirimycin' refers to the chemical (2R,3R,4R,5S)-
2-
(hydroxymethyl)-3,4,5-piperideinetriol, (CAS Registry No. 19130-96-2), also
known as D-5-
amino- 1,5-dideoxyglucopyranose, 1,5-dideoxy-1,5-imino-D-glucitol,
(2R,3R,4R,5S)-2-
hydroxymethyl-3,4,5-trihydroxypiperidine, or moranoline. Additionally, as used
herein,
`deoxynojirimycin' also includes derivatives of deoxynojirimycin such as
esters and salts.
3
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
[0017] As used herein, `deoxygalactonojirimycin' refers to the chemical 2-
(hydroxymethyl)piperidine-3,4,5-triol, (CAS Registry No. 75172-81-5), also
known as 1,5-
dideoxy-1,5-imino-D-galactitol, or galactostatin. Additionally, as used here,
`deoxygalactonojirimycin' also includes derivatives of deoxygalactonojirimycin
such as
esters and salts.
[0018] As used herein, `deoxymannojirimycin' refers to the chemical
(2R,3R,4R,5R)-2-
(hydroxymethyl)piperidine-3,4,5-triol, (CAS Registry No. 73465-43-7), also
known as 1,5-
dideoxy-1,5-imino-D-mannitol. Additionally, as used here,
`deoxymannojirimycin' also
includes derivatives of deoxymannojirimycin such as esters and salts.
[0019] As used herein, `homomannojirimycin' refers to the chemical
(2R,3R,5R,6R)-2,6-
bis(hydroxymethyl)piperidine-3,4,5-triol, (CAS Registry No. 127995-29-3).
Additionally, as
used here, `homomannojirimycin' also includes derivatives of
homomannojirimycin such as
esters and salts.
[0020] As used herein, `homonojirimycin' refers to the chemical (2R,3R,5S,6R)-
2,6-
bis(hydroxymethyl)piperidine-3,4,5-triol, (CAS Registry No. 119557-99-2).
Additionally, as
used here, `homonojirimycin' also includes derivatives of homonojirimycin such
as esters
and salts.
[0021] As used herein, the term `subject' refers to mammals and non-mammals.
Mammals
refers to any member of the mammalia class including, but not limited to,
humans; non-
human primates such as chimpanzees and other apes and monkey species; farm
animals such
as cattle, horses, sheep, goats, and swine; domestic animals such as rabbits,
dogs, and cats;
laboratory animals including rodents, such as rats, mice, and guinea pigs; and
the like.
Examples of non-mammals include, but are not limited to, birds, and the like.
[0022] As used herein, `citric acid' refers to the chemical 2-hydroxy- 1,2,3 -
propane-
tricarboxylic acid, (CAS Registry No. 77-92-9), also known as, (3-
hydroxytricarboxylic acid.
Additionally, as used herein, `citric acid' also includes derivatives of
citrate such as esters,
amides, and salts, as well as other derivatives, including derivatives having
pharmacoproperties upon metabolism to an active form.
[0023] As used herein, `maleic acid' refers to the chemical (Z)-butenedioic
acid, (CAS
registry No. 110-16-7), also known as toxilic acid, cis-l,2-
ethylenedicarboxylic acid.
Additionally, as used herein, `maleic acid' also includes derivatives of
maleic acid such as
esters, amides, and salts, as well as other derivatives, including derivatives
having
pharmacoproperties upon metabolism to an active form.
4
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
[0024] As used herein, `malic acid' refers to the chemical 1-Hydroxy-1,2-
ethanedicarboxylic acid, (CAS Registry No. 6915-15-17), also known as,
hydroxybutanedioic
acid, hydroxysuccinic acid, malate, or 2-hydroxybutanedioate. Additionally, as
used herein,
`malic acid' also includes derivatives of malate such as esters, amides, and
salts, as well as
other derivatives, including derivatives having pharmacoproperties upon
metabolism to an
active form.
[0025] As used herein, `fumaric acid' refers to the chemical (E)-2-butenedioic
acid, (CAS
Registry No. 110-17-8), also known as, trans-l,2-ethylenedicarboxylic acid,
allomaleic acid,
and boletic acid. Additionally, as used herein, `fumaric acid' also includes
derivatives of
fumarate such as esters, amides, and salts, as well as other derivatives,
including derivatives
having pharmacoproperties upon metabolism to an active form.
[0026] As used herein, the term `organic acid' refers to organic compounds
which contain
carboxylic acids (-C(O)OH). Typical examples of organic acids include, but are
not limited
to; malic acid, fumaric acid, citric acid, orotic acid, lactic acid, pyruvic
acid, and tartaric acid.
[0027] As used here, the term `acceptable oral dosage form' would be known by
one of skill
in the art to include, for example, powder beverage mixes, liquid beverages,
ready-to-eat
bars, capsules, liquid capsules, tablets, capleta, dietary gels, soft-gelTM
caplets, and gel-caps.
[0028] As used here, the term `parenteral' refers to methods of administration
of nutrients to
that region outside of the digestive tract. Examples of parenteral routes of
administration
include, but are not limited to, subcutaneous, intramuscular or intravenous
injection, and
nasopharyngeal, mucosal or transdermal absorption.
[0029] As used herein, the term `pharmaceutically-acceptable salt' refers to
acid-addition
salts of creatine imino sugar amides with an inorganic or organic acid such as
hydrochloric,
hydrobromic, sulphuric, trifluoroacetic, citric, maleic, malic, or fumaric
acid.
[0030] The term `pharmaceutically acceptable carrier' is art-recognized and
refers to a
pharmaceutically-acceptable material, composition or vehicle, such as a liquid
or solid filler,
diluent, excipient, solvent or encapsulating material, involved in carrying or
transporting any
subject composition or component thereof. Each carrier must be `acceptable' in
the sense of
being compatible with the subject composition and its components and not
injurious to the
individual to which it is administered. Some examples of materials which may
serve as
pharmaceutically acceptable carriers include: (1) sugars, such as lactose,
glucose and sucrose;
(2) starches, such as corn starch and potato starch; (3) cellulose, and its
derivatives, such as
sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4)
powdered
tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa
butter; (9) oils, such as
5
CA 02698500 2011-09-07
peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and
soybean oil; (10)
glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol,
mannitol and
polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13)
agar; (14)
buffering agents, such as magnesium hydroxide and aluminum hydroxide; and (15)
other
non-toxic compatible substances employed in pharmaceutical formulations, and
combinations
thereof.
100311 As used herein, the term `nutritional composition' includes dietary
supplements, diet
supplements, nutritional supplements, supplemental compositions and
supplemental dietary
compositions or those similarly envisioned and termed compositions not
belonging to the
conventional definition of pharmaceutical interventions as is known in the
art. Furthermore,
`nutritional compositions' as disclosed herein belong to category of
compositions having at
least one physiological function when administered to a subject by
conventional routes of
administration.
100321 Alternatively, formulations and nutritional compositions belonging to
the present
invention may he considered to be nutraceuticals. As used herein, the term
`nutraceutical' is
recognized and used in the art to describe a specific chemical compound or
combination of
compounds found in, organic matter for example, which may prevent, ameliorate
or
otherwise confer benefits against an undesirable condition. As is known in the
art, the term
`nutraceutical' is used to refer any substance that is a food, a part of food,
or an extract of
food which is suitable for consumption by an individual and providing
physiological benefit
which may be medical or health-related. Furthermore, the term has been used to
refer to a
product isolated, extracted or purified from foods or naturally-derived
material suitable for
consumption by an individual and usually sold in medicinal forms, such as
caplets, tablets,
capsules, soft-gelTM caplets, gel-caps and the like, not associated with food.
[0033] According to the present invention, the compounds disclosed herein
comprise imino sugars bound to creatine. Furthermore, the imino sugars and
creatine are bound by an amide linkage and have a structure according to
Formula 1 by a method comprising at least the steps of, reacting creatine with
an amino protecting group to form a protected creatine; concentrating said
protected creatine; reacting an activated protected creatine with an imino
sugar
to form a protected creatine imino sugar amide; isolating and purifying said
protected creatine imino sugar amide; removing the protecting groups from said
protected creatine imino sugar amide; and concentrating and purifying the
deprotected creatine imino sugar amide. The aforementioned compounds can be
prepared, for example, according to the reaction as set forth for the purposes
of
the description in Scheme 1 below.
6
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
Scheme 1
Step 1:
OI
!L
1 00 I0I I0 NaHC03 / H2O O N I ~ I NJ OH
H2NyN " OH + X0 J~0 J1\0\( 0 NYO
p-dioxane
NH 0 C- r.t 0
`
2 3 2-4h 4 Step 2:
2:
H H O R,
H O N N A 11
R2 N R, + X O N 0 OH DCC; DCM JOYNJN N OH
HO VnOH 0 C-' r.t O N~OR2 OH
8-10h
OH kO OH
4 6
Step 3:
H O R,
O R,
OUNYN,_,k N OH trifluoroacetic acid : H2O (1:1) H2NyN J~N OH
0 NYORz n OH 1.5 -3.5 h ; r.t NH
k 0 OH R2 OH
OH
6 1
Ri = H, OH or CH2OH;
R2 = H, OH, CH3 or CH2OH;
and n = 0, 1 or 2
[0034] As an example in Scheme 1, Step 1, creatine (2) is dissolved in water
and an excess
of sodium bicarbonate (NaHCO3) is added with stirring and then cooled in an
ice-water bath.
5 The resultant solution is cooled in an ice-water bath and di-tert-butyl
carbonate (3), also
known as boc anhydride, is added as a solution inp-dioxane (also cooled). The
mixture is
then stirred at about 0 C for about one hour and allowed to warm to room
temperature
(-23 C) for between 2-4 hours. Water is added to the mixture and the aqueous
layer is
extracted twice with ethyl acetate. The resultant organic layer is then back
extracted twice
with a saturated sodium bicarbonate solution. The combined aqueous layers are
acidified to a
pH of 1 with 10% HC1 and then extracted three times with ethyl acetate. The
organic layers
are combined, dried over sodium sulfate, filtered and concentrated in vacuo.
The resultant
protected creatine (4) would be of sufficient purity to be used in subsequent
steps. It should
be noted at this step that any amino protecting group, as would be known to
one of skill in the
art, could be used in place of boc anhydride. Examples of amino protecting
groups include,
but are not limited to: 9-fluorenylmethyl carbamate, di-tent-butyl carbonate,
benzyl
7
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
carbamate, acetamide, trifluoroacetamide, phthalimide, benzylamine,
benzylideneamine, p-
toluenesulfonamide, most preferably, di-tert-butyl carbonate.
[00351 Step 2 describes the combining of an imino sugar (5) and the protected
creatine (4).
The two substrates, 5 and 4, are stirred in DCM and submersed in an ice-water
bath to bring
to the temperature of the reaction to about 0 C. After cooling, a solution of
dicyclohexylcarbodiimine (DCC) and DCM is added to the mixture of 5 and 4 with
vigorous
stirring; the DCC acts to activate the carboxylic acid of the protected
creatine in situ.
Following the addition of the DCC the reaction is allowed to warm to room
temperature
(-23 C) with constant agitation. Stirring is maintained overnight (between
about 8 and about
10 hours). The mixture is then filtered through Celite in order to remove any
by-products
and unreacted materials. The filtrate is then concentrated under reduced
pressure and purified
by flash chromatography through a silica gel packed column to yield the bis-
boc-protected
creatine imino sugar amide (6).
[0036] In the preferred embodiment of the present invention, deoxynojirimycin
is the imino
sugar used. However any imino sugar, as is known by one of skill in the art,
may be utilized
to synthesize a creatine imino sugar amide according to the method disclosed
herein.
[0037] Step 3 describes the removal of the two boc protecting groups from the
guanidine
group of 6, via acidification. The bis-boc-protected creatine imino sugar
amide (6) is
dissolved in a trifluoroacetic acid:H20 (1:1) mixture. The reaction is stirred
at room
temperature for between about 1.5 and about 3.5 hours. After the reaction is
complete the
mixture is concentrated under reduced pressure and then purified by flash
chromatography
through a silica gel packed column to yield the target amide, creatine imino
sugar amide (1).
[0038] According to an additional embodiment, the creatine imino sugar amide
of the
present invention may be formulated into nutritional compositions that may be
consumed in
any form. For instance, the dosage form of the nutritional compositions may be
provided as,
e.g. a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink
product, a capsule,
a liquid capsule, a tablet, a caplet, or as a dietary gel. The preferred
dosage forms of the
present invention are provided as a powder beverage mix.
[0039] Furthermore, the dosage form of the nutritional composition may be
provided in
accordance with customary processing techniques for herbal and nutritional
compositions in
any of the forms mentioned above. Additionally, the nutritional composition,
comprising the
creatine imino sugar amide may contain any appropriate number and type of
pharmaceutically acceptable carriers, as is well known in the art.
8
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
[0040] Compounds of an imino sugar and a creatine bound via an amide bond
offer
increased resistance to the cyclization of creatine while in solution. It is
commonly
understood that hydrolysis of amides is more difficult to accomplish than the
hydrolysis of
esters. While amides of creatine and an imino sugar would be more stable in
solution than
related esters, the salts of these amides of creatine and an imino sugar would
offer the further
advantage of enhanced nutritional and/or therapeutical efficacy due to
increased solubility.
[0041] According an aspect of the present invention, creatine imino sugar
amides combined
with an inorganic or organic acid to form a creatine imino sugar amide salts
are disclosed.
The creatine imino sugar amide salts can be prepared according to the details
set forth in the
description below.
[0042] In one step of the process, a creatine imino sugar amide is dissolved
in an excess of
hot lower alcohol. The lower alcohol is considered to be hot, as would be
known by one of
ordinary skill in the art. Preferably the lower alcohol is considered to be
hot when heated to a
temperature about 5 C below the boiling point of the corresponding lower
alcohol.
[0043] In various embodiments of the present invention, the creatine imino
sugar amide
may be selected, for example, from the group including of 1-methyl-I-(2-oxo-2-
((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-l-yl)ethyl)
guanidine, also
known as creatine deoxynojirimycin amide; 1-methyl-l-(2-oxo-2-((3S,4R,5S)-
3,4,5-
trihydroxy-2-(hydroxymethyl)piperidin-1-yl)ethyl)guanidine, also known as
creatine
deoxygalactonojirimycin amide; 1-methyl-l-(2-oxo-2-((2R,3R,4R,5R)-3,4,5-
trihydroxy-2-
(hydroxymethyl)piperidin-1-yl)ethyl)guanidine, also known as creatine
deoxymannojirimycin
amide; 1-methyl-l-(2-oxo-2-((2R,3R,5R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin- l -yl)ethyl)guanidine, also known as creatine
homomannojirimycin amide; and 1-methyl-l-(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-
trihydroxy-
2,6-bis(hydroxymethyl) piperidin-l-yl)ethyl)guanidine, also known as creatine
homonojirimycin amide. However, it should be noted that a creatine imino sugar
amine may
be made with any imino sugar as would be known by one of skill in the art, and
would be
acceptable for use in the present invention.
[0044] Additionally, in various embodiments of the present invention, the
lower alcohol
preferably is selected from the group consisting of methanol, ethanol,
propanol, and
isopropanol. These lower alcohols may be used singly or in admixture
containing two or
more alcohols.
[0045] In another step of the process, the inorganic or organic acid is
dissolved in an excess
of hot lower alcohol. The lower alcohol is considered to be hot, as would be
known by one
9
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
of ordinary skill in the art. Preferably the lower alcohol is considered to be
hot when heated
to a temperature about 5 C below the boiling point of the corresponding lower
alcohol.
[0046] In various embodiments of the present invention, the inorganic or
organic acid
preferably is selected from the group consisting of hydrochloric acid,
hydrobromic acid,
sulphuric acid, trifluoroacetic acid, citric acid, maleic acid, malic acid and
fumaric acid.
[0047] The order in which the creatine imino sugar amide and the inorganic or
organic acid
are dissolved is not critical. Both solutions prepared above are then mixed
together and
heated to about the boiling point of the corresponding lower alcohol. If there
are solids still
present after heating, the combined solution is filtered while hot to remove
any unreacted
starting materials. The combined solution is then allowed to cool to room
temperature,
covered and refrigerated or cooled until crystallization occurs, preferably
for between about
24 to about 48 hours. The resultant solid is filtered under vacuum and washed
with ice cold
lower alcohol, yielding the creatine imino sugar amide salt.
[0048] In larger scale preparations of the present invention, diethyl ether
can be added until
the cloud point, as would be known to one of skill in the art, is reached
after the mixture is
cooled to room temperature, after which the solution is refrigerated or cooled
to allow
crystallization to complete. This will facilitate greater precipitation of the
product thus
yielding more of the creatine imino sugar amide salt, which would be desired
in industrial
settings.
[0049] Creatine imino sugar amide salts are used advantageously alone or with
additional
active ingredients, such as, trace elements, vitamins, mineral substances, or
other amino acids
as well as, optionally, excipients usually used for the preparation of the
respective forms of
administration. The forms of administration include, particularly, all
varieties of tablets, both
those that are swallowed without being chewed, and tablets to be chewed or
dissolved in the
mouth of an individual, as well as those that are dissolved in a liquid before
being ingested by
an individual. The tablet forms include uncoated tablets, one-layer or
multilayer or encased
forms or effervescent tablets. Further preferred forms of administration are
capsules of hard
and soft gelatin, the latter being particularly suitable to include a liquid
core. Additionally,
creatine imino sugar amide salts can be used advantageously for the
preparation of solutions
and suspensions and as a powder, either effervescent or granulated.
[0050] Creatine imino sugar amide salts of the present invention may, for
example include:
1. 1-methyl-l-(2-oxo-2-((2R,3R,4R,5 S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-1-
yl)ethyl)guanidine hydrochloride;
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
2. 1-methyl-i -(2-oxo-2-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin- l -
yl)ethyl)guanidine hydrobromide;
3. 1-methyl-l-(2-oxo-2-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin- l-
yl)ethyl)guanidine sulfate;
4. 1-methyl-l-(2-oxo-2-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-l-
yl)ethyl)guanidine hemisulfate;
5. 1-methyl-l-(2-oxo-2-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-1-
yl)ethyl)guanidine 2,2,2-trifluoroacetate;
6. 1-methyl-l -(2-oxo-2-((2R,3R,4R,5 S)-3,4,5-trihydroxy-2-(hydroxy-
methyl)piperidin-
1 -yl)ethyl)guanidine-2-hydroxypropane- 1,2,3-tricarboxylate;
7. 1-methyl- l -(2-oxo-2-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxy-
methyl)piperidin-
1-yl)ethyl)guanidine-hemi(2-hydroxypropane-1,2,3-tricarboxylate);
8. tris(1-methyl-l-(2-oxo-2-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxy-
methyl)piperidin- I -yl)ethyl)guanidine)-2-hydroxypropane- 1,2,3 -
tricarboxylate;
9. 1-methyl-l-(2-oxo-2-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-l-
yl)ethyl)guanidine maleate;
10. 1-methyl- l -(2-oxo-2-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1-yl)ethyl)guanidine hemimaleate;
11. 1-methyl- l -(2-oxo-2-((2R,3 R,4R,5 S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1-yl)ethyl)guanidine malate;
12. 1-methyl- l -(2-oxo-2-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1-yl)ethyl)guanidine hemimalate;
13. 1-methyl- l -(2-oxo-2-((2R,3 R,4R,5 S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1-yl)ethyl)guanidine fumarate;
14. 1-methyl- l -(2-oxo-2-((2R,3R,4R,5 S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1-yl)ethyl)guanidine hemifumarate;
15. 1-methyl- l -(2-oxo-2-((3 S,4R,5 S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin- l -
yl)ethyl)guanidine hydrochloride;
16. 1-methyl- l -(2-oxo-2-((3 S,4R,5 S)-3,4, 5-trihydroxy-2-(hydroxy-
methyl)piperidin- l -
yl)ethyl)guanidine hydrobromide;
17. 1-methyl-l -(2-oxo-2-((3 S,4R,5S)-3,4,5-trihydroxy-2-(hydroxy-
methyl)piperidin- l-
yl)ethyl)guanidine sulfate;
18. 1-methyl- l -(2-oxo-2-((3 S,4R, 5 S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin- l -
yl)ethyl)guanidine hemisulfate;
11
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
19. 1-methyl- l -(2-oxo-2-((3 S,4R,5S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin- l -
yl)ethyl)guanidine 2,2,2-trifluoroacetate;
20. 1-methyl- l -(2-oxo-2-((3 S,4R,5 S)-3,4,5-trihydroxy-2-(hydroxy-
methyl)piperidin- l -
yl)ethyl)guanidine-2-hydroxypropane-1,2,3-tricarboxylate;
21. 1-methyl-l-(2-oxo-2-((3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxy-
methyl)piperidin-l-
yl)ethyl)guanidine-hemi(2-hydroxypropane-1,2,3-tricarboxylate);
22. tris(1-methyl-l -(2-oxo-2-((3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxy-
methyl)piperidin-
1-yl)ethyl)guanidine)-2-hydroxypropane-1,2,3 -tricarboxylate;
23. 1-methyl-l -(2-oxo-2-((3S,4R,5S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-l-
yl)ethyl)guanidine maleate;
24. 1-methyl- l -(2-oxo-2-((3 S,4R, 5 S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin- l -
yl)ethyl)guanidine hemimaleate;
25. 1-methyl- l -(2-oxo-2-((3 S,4R,5 S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin- l -
yl)ethyl)guanidine malate;
26. 1-methyl-l-(2-oxo-2-((3S,4R,5S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-l-
yl)ethyl)guanidine hemimalate;
27. 1-methyl-l -(2-oxo-2-((3 S,4R,5S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-l-
yl)ethyl)guanidine fumarate;
28. 1-methyl- l -(2-oxo-2-((3 S,4R,5 S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin- l -
yl)ethyl)guanidine hemifumarate;
29. 1-methyl- l -(2-oxo-2-((2R,3 R,4R,5R)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1-yl)ethyl)guanidine hydrochloride;
30. 1-methyl- l -(2-oxo-2-((2R,3R,4R, 5R)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1-yl)ethyl)guanidine hydrobromide;
31. 1-methyl-l-(2-oxo-2-((2R,3R,4R,5R)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1-yl)ethyl)guanidine sulfate;
32. 1-methyl-l-(2-oxo-2-((2R,3R,4R,5R)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1 -yl)ethyl)guanidine hemisulfate;
33. 1-methyl- l -(2-oxo-2-((2R,3R,4R,5R)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1-yl)ethyl)guanidine 2,2,2-trifluoroacetate;
34. 1-methyl-l -(2-oxo-2-((2R,3R,4R,5R)-3,4,5-trihydroxy-2-(hydroxy-
methyl)piperidin-
1-yl)ethyl)guanidine-2-hydroxypropane-1,2, 3-tricarboxylate;
35. 1-methyl- l -(2-oxo-2-((2R,3R,4R,5R)-3,4,5-trihydroxy-2-(hydroxy-
methyl)piperidin-
1-yl)ethyl)guanidine-hemi(2-hydroxypropane-1,2,3-tricarboxylate);
12
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
36. tris(1-methyl-l-(2-oxo-2-((2R,3R,4R,5R)-3,4,5-trihydroxy-2-(hydroxy-
methyl)piperidin- l -yl)ethyl)guanidine)-2-hydroxypropane-1,2,3 -
tricarboxylate;
37. 1-methyl-l -(2-oxo-2-((2R,3R,4R,5R)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1-yl)ethyl)guanidine maleate;
38. 1-methyl-l-(2-oxo-2-((2R,3R,4R,5R)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1-yl)ethyl)guanidine hemimaleate;
39. 1-methyl-l -(2-oxo-2-((2R,3R,4R,5R)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1-yl)ethyl)guanidine malate;
40. 1-methyl- l -(2-oxo-2-((2R,3 R,4R,5R)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1-yl)ethyl)guanidine hemimalate;
41. 1-methyl-l -(2-oxo-2-((2R,3R,4R,5R)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1-yl)ethyl)guanidine fumarate;
42. 1-methyl-l -(2-oxo-2-((2R,3R,4R,5R)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-
1 -yl)ethyl)guanidine hemifumarate;
43. 1-methyl-l-(2-oxo-2-((2R,3R,5R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-1-yl)ethyl)guanidine hydrochloride;
44. 1-methyl- l -(2-oxo-2-((2R,3 R, 5R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-1-yl)ethyl)guanidine hydrobromide;
45. 1-methyl-l-(2-oxo-2-((2R,3R,5R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-1-yl)ethyl)guanidine sulfate;
46. 1-methyl-l -(2-oxo-2-((2R,3R,5R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-1-yl)ethyl)guanidine hemisulfate;
47. 1-methyl- l -(2-oxo-2-((2R,3R,5R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-1-yl)ethyl)guanidine 2,2,2-trifluoroacetate;
48. 1-methyl-l-(2-oxo-2-((2R,3R,5R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin- l -yl)ethyl)guanidine-2-hydroxypropane- 1,2,3 -
tricarboxylate;
49. 1-methyl- l -(2-oxo-2-((2R,3R,5R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin- l -yl)ethyl)guanidine-hemi(2-hydroxypropane-1,2,3-
tricarboxylate);
50. tris(1-methyl-l-(2-oxo-2-((2R,3R,5R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-1-yl)ethyl)guanidine)-2-hydroxypropane-1,2,3-
tricarboxylate;
13
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
51. 1-methyl- l -(2-oxo-2-((2R,3R,5R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-l-yl)ethyl)guanidine maleate;
52. 1-methyl- l -(2-oxo-2-((2R,3R, 5R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-1-yl)ethyl)guanidine hemimaleate;
53. 1-methyl-l -(2-oxo-2-((2R,3R,5R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-l-yl)ethyl)guanidine malate;
54. 1-methyl- l -(2-oxo-2-((2R,3R,5R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-1-yl)ethyl)guanidine hemimalate;
55. 1-methyl- l -(2-oxo-2-((2R,3R, 5R,6R)-3,4, 5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-1-yl)ethyl)guanidine fumarate;
56. 1-methyl-l -(2-oxo-2-((2R,3R,5R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-l-yl)ethyl)guanidine hemifumarate;
57. 1-methyl-l -(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-1-yl)ethyl)guanidine hydrochloride;
58. 1-methyl-l-(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-l-yl)ethyl)guanidine hydrobromide;
59. 1-methyl- l -(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-1-yl)ethyl)guanidine sulfate;
60. 1-methyl-l-(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-l-yl)ethyl)guanidine hemisulfate;
61. 1-methyl-l -(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin- l -yl)ethyl)guanidine 2,2,2-trifluoroacetate;
62. 1-methyl- l -(2-oxo-2-((2R,3R,4S,5 S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-l-yl)ethyl)guanidine 2-hydroxypropane- 1,2,3 -
tricarboxylate;
63. 1-methyl-l-(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-1-yl)ethyl)guanidine hemi(2-hydroxypropane-1,2,3-
tricarboxylate);
64. tris(1-methyl-l-(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-1-yl)ethyl)guanidine) 2-hydroxypropane-1,2,3-
tricarboxylate;
65. 1-methyl- l -(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-l-yl)ethyl)guanidine maleate;
14
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
66. 1-methyl-l -(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin- I -yl)ethyl)guanidine hemimaleate;
67. 1-methyl- l -(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-1-yl)ethyl)guanidine malate;
68. 1-methyl-l-(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-l-yl)ethyl)guanidine hemimalate;
69. 1-methyl-l -(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin- l -yl)ethyl)guanidine fumarate; and
70. 1-methyl-l -(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-l-yl)ethyl)guanidine hemifumarate.
[00511 The non-limiting examples given above provide examples of creatine
imino sugar
amides salts which are within the present invention. One of skill in the art
may readily
envision various other salts within the scope of the present invention,
considering the
examples with reference to the specification herein provided.
100521 The following non-limiting example illustrates feasible synthesis of
various creatine
imino sugar amides and salts thereof. One of skill in the art may readily
envision various
other combinations within the scope of the present invention, considering the
example with
reference to the specification herein provided.
[00531 Also provided below is a method for producing creatine imino sugar
amide salts of
the present invention. Provided with the present specification, those of skill
in the art will
readily appreciate that certain modifications and variations may be made in
the process of
"scaling-up" the reaction to manufacture larger batches of creatine imino
sugar amide salts
which may be required or useful for commercial uses and supply requirements.
Other
methods of synthesis may also be apparent to those of skill in the art.
[00541 Furthermore, it would be known by one of skill in the art that varying
the
stoichiometric ratios of the various creatine imino sugar amides to the
inorganic or organic
acids will results in various salts. For example using equimolar ratios of
creatine
deoxynojirimycin amide and malic acid will lead to creatine deoxynojirimycin
amide malate,
whereas using 2 molar equivalents of creatine deoxynojirimycin amide for every
1 molar
equivalent of malic acid will lead to creatine deoxynojirimycin amide
hemimalate.
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
Examples
Example 1
1-methyl- l -(2-oxo-2-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-1-
yl)ethyl)guanidine
OH
0
H2N YN"-A OH
N
NH
V'O O H
OH
[0055] In a round bottomed flask, equipped with a magnetic stirrer, 7.87 g
(0.060mol) of
creatine is dissolved in 200 mL of water and 10.08 g (0.120mol) of sodium
bicarbonate is
added with stirring. The solution is then cooled to about about 0 C in an ice-
water bath. To
the cooled solution is added a cooled solution of 31.10 ml (0.150mol) of di-
tert-butyl
dicarbonate dissolved in 150 mL ofp-dioxane. The mixture is then stirred at
about 0 C in an
ice-water bath for an hour, after which the ice bath is removed and the
solution is allowed to
warm to room temperature (-23 C). After stirring at room temperature for an
additional 2
hours, the mixture is diluted with 150 mL of water and transferred to a 1-L
separatory funnel,
where the aqueous layer is extracted sequentially with one 300 mL and one 150
mL portions
of ethyl acetate. The resultant organic layer is then back extracted
sequentially one 150 mL
and one 75 mL portions of saturated sodium bicarbonate solution. The combined
aqueous
portions are then slowly acidified to a pH of 1, in a 1-L separatory funnel,
with 10% HCI, and
then extracted with three 100 mL ethyl acetate portions. The organic layers
are then
combined, dried over sodium sulphate, filtered and then concentrated under
reduced pressure.
The resultant 2-(2,3-bis(tert-butoxycarbonyl)-1-methylguanidino)acetic acid
would be
sufficiently pure to use in subsequent steps.
[0056] A dry, 2-necked round bottomed flask, equipped with a magnetic stirrer
and a
dropping funnel containing a solution of 10.83 g (0.0525mo1) of N,N'-
dicyclohexylcarbodiimide (DCC) dissolved in 125 mL of DCM, is charged with
16.57g
(0.050mol) of 2-(2,3-bis(tert-butoxycarbonyl)-1-methylguanidino)acetic acid,
8.97 g
(0.055mo1) of deoxynojirimycin, and 100mL of DCM (all of which is under an
argon
atmosphere). The resultant mixture is stirred in an ice-water bath to cool the
solution to a
temperature of about 0 C. Following cooling, the solution of DCC from the
dropping funnel
16
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
is added and the reaction is allowed to warm to room temperature and then to
stir overnight.
The mixture is then filtered through a Celite plug and the filtrate is
purified by flash
chromatography (ethyl acetate/hexanes; 1/3) to yield the bis-boc protected
creatine
deoxynojirimycin amide, tert-butyl (tert-butoxycarbonylamino)(methyl(2-oxo-2-
((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-l-
yl)ethyl)amino)methylene-
carbamate.
100571 In a dry, round bottomed flask, equipped with a magnetic stirrer, 19.06
g (0.040mol)
of tert-butyl (tert-butoxycarbonylamino)(methyl(2-oxo-2-((2R,3R,4R,5S)-3,4,5-
trihydroxy-2-
(hydroxymethyl)piperidin-1-yl)ethyl)amino) methylenecarbamate is dissolved in
250 mL of a
trifluoroacetic acid:H20 (1:1) mixture. The resultant mixture is stirred for
1.5 hours at room
temperature, after which it is concentrated under reduced pressure and then
purified by flash
chromatography (ethyl acetate/hexanes; 1/5) to yield the creatine
deoxynojirimycin amide, 1-
methyl- l -(2-oxo-2-((2R,3 R,4R, 5 S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-I-
yl)ethyl)guanidine.
Example 2
1-methyl- l -(2-oxo-2-((3 S,4R,5 S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-l-
yl)ethyl)guanidine
OH
0
H2N Y N_'_~ N ,,,OH
NH
"O H
OH
[00581 In a round bottomed flask, equipped with a magnetic stirrer, 6.50 g
(0.050mol) of
creatine is dissolved in 175 mL of water and 8.40 g (0. l Omol) of sodium
bicarbonate is added
with stirring. The solution is then cooled to about 0 C in an ice-water bath.
To the cooled
solution is added a cooled solution of 28.72 ml (0.10mol) of di-tert-butyl
dicarbonate
dissolved in 125 mL ofp-dioxane. The mixture is then stirred at 0 C in an ice-
water bath for
an hour, after which the ice-water bath is removed and the solution is allowed
to warm to
room temperature (-23 C). After stirring at room temperature for an additional
2 hours, the
mixture is diluted with 150 mL of water and transferred to a 1-L separatory
funnel, where the
aqueous layer is extracted sequentially with one 300 mL and one 150 mL
portions of ethyl
acetate. The resultant organic layer is then back extracted sequentially one
150 mL and one
75 mL portions of saturated sodium bicarbonate solution. The combined aqueous
portions
17
CA 02698500 2010-04-27
WO 2009/143630, PCT/CA2009/000757
are then slowly acidified to a pH of 1, in a 1-L separatory funnel, with 10%
HC1, and then
extracted with three 100 mL ethyl acetate portions. The organic layers are
then combined,
dried over sodium sulphate, filtered and then concentrated under reduced
pressure. The
resultant 2-(2,3-bis(tert-butoxycarbonyl)-1-methylguanidino)acetic acid would
be sufficiently
pure to use in subsequent steps.
[0059] A dry, 2-necked round bottomed flask, equipped with a magnetic stirrer
and a
dropping funnel containing a solution of 8.66 g (0.042mo1) of N,N'-
dicyclohexylcarbodiimide
(DCC) dissolved in 100 mL of DCM, is charged with 13.25 g (0.040mol) of 2-(2,3-
bis(tert-
butoxycarbonyl)-1-methylguanidino)acetic acid, 7.18 g (0.044mo1) of
deoxygalactonojirimycin, and 75 mL of DCM (all of which is under an argon
atmosphere).
The resultant mixture is stirred in an ice-water bath to cool the solution to
a temperature of
about 0 C. Following cooling, the solution of DCC from the dropping funnel is
added and
the reaction is allowed to warm to room temperature and then to stir
overnight. The mixture
is then filtered through a Celite plug and the filtrate is purified by flash
chromatography
(ethyl acetate/hexanes; 1/3) to yield the bis-boc protected creatine
deoxygalactonojirimycin
amide, tert-butyl(tert-butoxycarbonylamino)(methyl(2-oxo-2-((3S,4R,5S)-3,4,5-
trihydroxy-2-
(hydroxymethyl)piperidin- l -yl)ethyl)amino) methylenecarbamate.
[0060] In a dry, round bottomed flask, equipped with a magnetic stirrer, 23.81
g (0.050mol)
of tert-butyl(tert-butoxycarbonylamino)(methyl(2-oxo-2-((3S,4R,5S)-3,4,5-
trihydroxy-2-
(hydroxymethyl)piperidin- l -yl)ethyl)amino) methylenecarbamate is dissolved
in 275 mL of a
trifluoroacetic acid:H20 (1:1) mixture. The resultant mixture is stirred for 2
hours at room
temperature, after which it is concentrated under reduced pressure and then
purified by flash
chromatography (ethyl acetate/hexanes; 2/3) to yield the creatine
deoxygalactonojirimycin
amide, 1-methyl-l-(2-oxo-2-((3S,4R,5S)-3,4,5-trihydroxy -2-
(hydroxymethyl)piperidin-l-
yl)ethyl)guanidine.
Example 3
1-methyl- l -(2-oxo-2-((2R,3 R,4R,5 R)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin- l -
yl)ethyl)guanidine
1OH
O
H2N Y N__~ N OH
NH
OH
OH
18
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
[0061] In a round bottomed flask, equipped with a magnetic stirrer, 9.17 g
(0.070mol) of
creatine is dissolved in 300 mL of water and 11.76 g (0.140mo1) of sodium
bicarbonate is
added with stirring. The solution is then cooled to about 0 C in an ice-water
bath. To the
cooled solution is added a cooled solution of 40.20 ml (0.175mo1) of di-tert-
butyl dicarbonate
dissolved in 175 mL ofp-dioxane. The mixture is then stirred at about 0 C in
an ice-water
bath for an hour, after which the ice-water bath is removed and the solution
is allowed to
warm to room temperature (-23 C). After stirring at room temperature for an
additional 3
hours, the mixture is diluted with 250 mL of water and transferred to a 2-L
separatory funnel,
where the aqueous layer is extracted sequentially with one 300 mL and one 150
mL portions
of ethyl acetate. The resultant organic layer is then back extracted
sequentially one 150 mL
and one 75 mL portions of saturated sodium bicarbonate solution. The combined
aqueous
portions are then slowly acidified to a pH of 1, in a 2-L reparatory funnel,
with 10% HCI, and
then extracted with three 100 mL ethyl acetate portions. The organic layers
are then
combined, dried over sodium sulphate, filtered and then concentrated under
reduced pressure.
The resultant 2-(2,3-bis(tert-butoxycarbonyl)-1-methyl-guanidino)acetic acid
would be
sufficiently pure to use in subsequent steps.
[0062] A dry, 2-necked round bottomed flask, equipped with a magnetic stirrer
and a
dropping funnel containing a solution of 13.00 g (0.063mo1) of N,N'-
dicyclohexylcarbodiimide (DCC) dissolved in 150 mL of DCM, is charged with
19.88 g
(0.060mol) of 2-(2,3-bis(tert-butoxycarbonyl)-1-methylguanidino)acetic acid,
10.77 g
(0.066mo1) of deoxymannojirimycin, and 150mL of DCM (all of which is under an
argon
atmosphere). The resultant mixture is stirred in an ice-water bath to cool the
solution to a
temperature of about 0 C. Following cooling, the solution of DCC from the
dropping funnel
is added and the reaction is allowed to warm to room temperature and then to
stir overnight.
The mixture is then filtered through a Celite plug and the filtrate is
purified by flash
chromatography (ethyl acetate/hexanes; 1/3) to yield the bis-boc protected
creatine
deoxymannojirimycin amide, tert-butyl (tert-butoxycarbonylamino)(methyl(2-oxo-
2-
((2R,3R,4R,5R)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin- l -yl)ethyl)amino)
methylenecarbamate.
[0063] In a dry, round bottomed flask, equipped with a magnetic stirrer, 30.96
g (0.065mo1)
of tert-butyl (tert-butoxycarbonylamino)(methyl(2-oxo-2-((2R,3R,4R,5R)-3,4,5-
trihydroxy-2-
(hydroxymethyl)piperidin-1-yl)ethyl)amino) methylenecarbamate is dissolved in
325 mL of a
trifluoroacetic acid:H20 (1:1) mixture. The resultant mixture is stirred for 3
hours at room
temperature, after which it is concentrated under reduced pressure and then
purified by flash
19
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
chromatography (ethyl acetate/hexanes; 1/5) to yield the creatine
deoxymannojirimycin
amide, 1-methyl-l-(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-1-yl)ethyl)guanidine.
Example 4
1-methyl- l -(2-oxo-2-((2R,3R,5 R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-l-
yl)ethyl)guanidine
OH
0
H2N Y N"-A N OH
NH HO
OH
OH
[00641 In a round bottomed flask, equipped with a magnetic stirrer, 3.93 g
(0.030mol) of
creatine is dissolved in 150 mL of water and 5.04 g (0.060mol) of sodium
bicarbonate is
added with stirring. The solution is then cooled to about 0 C in an ice-water
bath. To the
cooled solution is added a cooled solution of 17.24 mL (0.075mo1) of di-tert-
butyl
dicarbonate dissolved in 100 mL ofp-dioxane. The mixture is then stirred at
about 0 C in an
ice-water bath for an hour, after which the ice-water bath is removed and the
solution is
allowed to warm to room temperature (-23 C). After stirring at room
temperature for an
additional hour, the mixture is diluted with 125 mL of water and transferred
to a 1-L
separatory funnel, where the aqueous layer is extracted sequentially with one
200 mL and one
75 mL portions of ethyl acetate. The resultant organic layer is then back
extracted
sequentially one 100 mL and one 50 mL portions of saturated sodium bicarbonate
solution.
The combined aqueous portions are then slowly acidified to a pH of 1, in a 1-L
separatory
funnel, with 10% HCI, and then extracted with three 75 mL ethyl acetate
portions. The
organic layers are then combined, dried over sodium sulphate, filtered and
then concentrated
under reduced pressure. The resultant 2-(2,3-bis(tert-butoxycarbonyl)-1-methyl-
guanidino) acetic acid would be sufficiently pure to use in subsequent steps.
[00651 A dry, 2-necked round bottomed flask, equipped with a magnetic stirrer
and a
dropping funnel containing a solution of 6.50 g (0.0315mol) of N,N'-
dicyclohexylcarbodiimide (DCC) dissolved in 80 mL of DCM, is charged with 9.94
g
(0.030mol) of 2-(2,3-bis(tert-butoxycarbonyl)-1-methylguanidino)acetic acid,
6.38 g
(0.033mo1) of homomannojirimycin, and 100mL of DCM (all of which is under an
argon
atmosphere). The resultant mixture is stirred in an ice-water bath to cool the
solution to a
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
temperature of about 0 C. Following cooling, the solution of DCC from the
dropping funnel
is added and the reaction is allowed to warm to room temperature and then to
stir overnight.
The mixture is then filtered through a Celite plug and the filtrate is
purified by flash
chromatography (ethyl acetate/hexanes; 1/3) to yield the bis-boc protected
creatine
homomannojirimycin amide, tert-butyl (tert-butoxycarbonylamino)(methyl(2-oxo-2-
((2R,3 R,5 R,6R)-3,4,5-trihydroxy-2,6-bis(hydroxymethyl)piperidin- l -
yl)ethyl)amino)methylene-carbamate.
[0066] In a dry, round bottomed flask, equipped with a magnetic stirrer, 10.12
g (0.020mol)
of tent-butyl(tert-butoxycarbonylamino)(methyl(2-oxo-2-((2R,3R,5R,6R)-3,4,5-
trihydroxy-
2,6-bis(hydroxymethyl)piperidin-1-yl)ethyl) amino)methylenecarbamate is
dissolved in 150
mL of a trifluoroacetic acid:H20 (1:1) mixture. The resultant mixture is
stirred for 2 hours at
room temperature, after which it is concentrated under reduced pressure and
then purified by
flash chromatography (ethyl acetate/hexanes; 1/5) to yield the creatine
homomannojirimycin
amide, 1-methyl-l-(2-oxo-2-((2R,3R,5R,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-l-yl)ethyl)guanidine.
Example 5
1-methyl-l-(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-2,6-
bis(hydroxymethyl)piperidin-
1-yl)ethyl)guanidine
/OH
0
H2N N,"A N ,,,OH
Y
NH HO
0H
OH
[0067] In a round bottomed flask, equipped with a magnetic stirrer, 7.87 g
(0.060mol) of
creatine is dissolved in 200 mL of water and 10.08 g (0.120mol) of sodium
bicarbonate is
added with stirring. The solution is then cooled to about 0 C in an ice-water
bath. To the
cooled solution is added a cooled solution of 31. 10 ml (0.150mol) of di-tert-
butyl dicarbonate
dissolved in 150 mL ofp-dioxane. The mixture is then stirred at about 0 C in
an ice-water
bath for an hour, after which the ice-water bath is removed and the solution
is allowed to
warm to room temperature (-23 C). After stirring at room temperature for an
additional 2
hours, the mixture is diluted with 150 mL of water and transferred to a 1-L
separatory funnel,
where the aqueous layer is extracted sequentially with one 300 mL and one 150
mL portions
of ethyl acetate. The resultant organic layer is then back extracted
sequentially one 150 mL
21
CA 02698500 2010-04-27
WO 2009/143630 PCT/CA2009/000757
and one 75 mL portions of saturated sodium bicarbonate solution. The combined
aqueous
portions are then slowly acidified to a pH of 1, in a 1-L separatory funnel,
with 10% HCI, and
then extracted with three 100 mL ethyl acetate portions. The organic layers
are then
combined, dried over sodium sulphate, filtered and then concentrated under
reduced pressure.
The resultant 2-(2,3-bis(tert-butoxycarbonyl)-1-methyl-guanidino)acetic acid
would be
sufficiently pure to use in subsequent steps.
[0068] A dry, 2-necked round bottomed flask, equipped with a magnetic stirrer
and a
dropping funnel containing a solution of 10.83 g (0.0525mo1) of N,N'-
dicyclohexylcarbodiimide (DCC) dissolved in 60 mL of DCM, is charged with
16.57 g
(0.050mol) of 2-(2,3-bis(tert-butoxycarbonyl)-1-methylguanidino)acetic acid,
10.62 g
(0.055mol) of homonojirimycin, and 100mL of DCM (all of which is under an
argon
atmosphere). The resultant mixture is stirred in an ice-water bath to cool the
solution to a
temperature of about 0 C. Following cooling, the solution of DCC from the
dropping funnel
is added and the reaction is allowed to warm to room temperature and then to
stir overnight.
The mixture is then filtered through a Celite plug and the filtrate is
purified by flash
chromatography (ethyl acetate/hexanes; 1/3) to yield the bis-boc protected
creatine
homonojirimycin amide, tert-butyl(tert-butoxycarbonylamino)(methyl(2-oxo-2-
((2R,3 R,4S,5 S,6R)-3,4, 5-trihydroxy-2,6-bis(hydroxymethyl)piperidin- l -
yl)ethyl)amino)methylene-carbamate.
[0069] In a dry, round bottomed flask, equipped with a magnetic stirrer, 20.62
g (0.040mol)
of tert-butyl (tert-butoxycarbonylamino)(methyl(2-oxo-2-((2R,3R,4S,5S,6R)-
3,4,5-
trihydroxy-2,6-bis(hydroxymethyl)piperidin-l-yl)ethyl)
amino)methylenecarbamate is
dissolved in 250 mL of a trifluoroacetic acid:H20 (1:1) mixture. The resultant
mixture is
stirred for 2 hours at room temperature, after which it is concentrated under
reduced pressure
and then purified by flash chromatography (ethyl acetate/hexanes; 1/5) to
yield the creatine
homonojirimycin amide, 1-methyl-l-(2-oxo-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-
2,6-
bis(hydroxymethyl)piperidin- l -yl)ethyl)guanidine.
Example 5
[0070] 552.58 g (2 mol) of creatine deoxynojirimycin amide is dissolved into
400mL of hot
ethanol, solution 1. Concurrently, 134.09 g (1 mol) of malic acid is dissolved
in 200mL of
hot ethanol, solution 2. Solution 2 is added to solution 1 with stirring and
the resultant
combined solution is heated to the boiling point. If there are solids still
present the combined
solution is filtered at this temperature to remove unreacted starting
materials. The combined
solution is then allowed to cool to room temperature and then covered and
refrigerated to
22
CA 02698500 2010-11-26
allow crystallization to complete; about 24 hours. The resultant crystals are
filtered under
vacuum and washed with ice cold ethanol, yielding the creatine
deoxynojirimycin amide
hemimalate.
Example 6
[0071] 552.58 g (2 mol) of creatine deoxygalactonojirimycin amide is dissolved
into 400
mL of hot propanol, solution 1. Concurrently, 116.07 g (1 mol) of fumaric acid
is dissolved in
200 mL of hot propanol, solution 2. Solution 2 is added to solution 1 with
stirring and the
resultant combined solution is heated to the boiling point. If there are
solids still present the
combined solution is filtered at this temperature to remove unreacted starting
materials. The
combined solution is then allowed to cool to room temperature and refrigerated
to allow
crystallization to complete; about 24 hours. The resultant crystals are
filtered under vacuum
and washed with ice cold ethanol, yielding the creatine
deoxygalactonojirimycin amide
hemifumarate.
Example 7
[0072] 828.27 g (3 mol) of creatine deoxymannojirimycin amide is dissolved
into 600
mL of hot isopropanol, solution 1. Concurrently, 192.12 g (1 mol) of citric
acid is dissolved
in 300 mL of hot isopropanol, solution 2. Solution 2 is added to solution 1
with stirring and
the resultant combined solution is heated to the boiling point. If there are
solids still present
the combined solution is filtered at this temperature to remove unreacted
starting materials.
The combined solution is then allowed to cool to room temperature and
refrigerated to allow
crystallization to complete; about 24 hours. The resultant crystals are
filtered under vacuum
and washed with ice cold ethanol, yielding the tris(creatine
deoxymannojirimycin amide)
citrate.
Extensions and Alternatives
[0073] In the foregoing specification, the invention has been described with
respect to
specific embodiments thereof; however, it will be evident to one skilled in
the art that various
modifications and changes may be made thereto without departing from the scope
of the
invention.
23
